ArticleEMBO reports2017
RNA activation-independent DNA targeting of the Type III CRISPR-Cas system by a Csm complex.
Article in EMBO reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Mass spectrometry based identification of AMP-O-Tris generated by Thermococcus onnurineus Cas10.FEBS open bio · 2026Article
- Precise transcript targeting by CRISPR-Csm complexes.Nature biotechnology · 2023Article
- Specificity and sensitivity of an RNA targeting type III CRISPR complex coupled with a NucC endonuclease effector.Nucleic acids research · 2021Article
- A type III-A CRISPR-Cas system mediates co-transcriptional DNA cleavage at the transcriptional bubbles in close proximity to active effectors.Nucleic acids research · 2021Article
- The Involvement ofFrontiers in microbiology · 2021Article
- Heavily Armed Ancestors: CRISPR Immunity and Applications in Archaea with a Comparative Analysis of CRISPR Types in Sulfolobales.Biomolecules · 2020Review
- Characterization of a novel type III CRISPR-Cas effector provides new insights into the allosteric activation and suppression of the Cas10 DNase.Cell discovery · 2020Article
- In vivo genome editing using the Cpf1 ortholog derived from Eubacterium eligens.Scientific reports · 2019Article
- Target sequence requirements of a type III-B CRISPR-Cas immune system.The Journal of biological chemistry · 2019Article
- The ribonuclease activity of Csm6 is required for anti-plasmid immunity by Type III-A CRISPR-Cas systems.RNA biology · 2019Article
- Type III-A CRISPR-Cas Csm Complexes: Assembly, Periodic RNA Cleavage, DNase Activity Regulation, and Autoimmunity.Molecular cell · 2019Article
- Structure Studies of the CRISPR-Csm Complex Reveal Mechanism of Co-transcriptional Interference.Cell · 2019Article
- Cryo-EM structure of Type III-A CRISPR effector complex.Cell research · 2018Article
- CRISPR-Based Technologies: Impact of RNA-Targeting Systems.Molecular cell · 2018Review
- RNA activation-independent DNA targeting of the Type III CRISPR-Cas system by a Csm complex.EMBO reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The CRISPR-Cas system is an adaptive and heritable immune response that destroys invading foreign nucleic acids. The effector complex of the Type III CRISPR-Cas system targets RNA and DNA in a transcription-coupled manner, but the exact mechanism of DNA targeting by this complex remains elusive. In this study, an effector Csm holocomplex derived from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.